NDAINTRAMUSCULARPOWDER
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
GEODON (ziprasidone mesylate) by Viatris (2) is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. First approved in 2002.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEODON (ziprasidone mesylate) is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5HT2 receptors. Administered via intramuscular injection, it is used to treat acute agitation in patients with schizophrenia and bipolar disorder. The drug offers rapid onset of action suited for acute psychiatric crises.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30%), the brand team is likely transitioning to defense and cost optimization rather than growth initiatives.
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Pharmacologic Class:
Atypical Antipsychotic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Geodon in Weight Loss Study for Bipolar Disorders
Started Jan 2007
25 enrolled
Bipolar Disorder
Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Started Dec 2006
73 enrolled
Bipolar DisorderBipolar DepressionDepression
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
Started Feb 2006
392 enrolled
Bipolar Disorder
A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression
Started Jul 2005
536 enrolled
Bipolar Disorder
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
Started Feb 2005
30 enrolled
Bipolar II DisorderMajor Depressive Episode
Worked on GEODON at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.